Valuation: Viking Therapeutics, Inc.

Market Cap 3.01B 2.69B 2.49B 2.25B 4.21B 286B 4.28B 29.91B 11.84B 150B 11.31B 11.07B 472B P/E 2026 *
-5.62x
P/E 2027 * -6.05x
Enterprise Value 2.55B 2.28B 2.1B 1.91B 3.57B 242B 3.63B 25.31B 10.02B 127B 9.57B 9.37B 400B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Viking Therapeutics, Inc.

1 day-4.94%
1 week-2.60%
Current month-24.80%
1 month-41.14%
3 months-30.73%
6 months-25.26%
Current year-30.32%
1 week 24.46
Extreme 24.46
27.29
1 month 24.46
Extreme 24.46
39.05
Current year 24.46
Extreme 24.46
43.1
1 year 24.46
Extreme 24.46
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 23/09/2012
Director of Finance/CFO 55 03/01/2021
Chief Tech/Sci/R&D Officer 57 10/06/2026
Director TitleAgeSince
Chairman 68 30/04/2015
Chairman 60 23/09/2012
Director/Board Member 53 30/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Free

Director

47,133 0.0404%
29/07/26 Sell

Chief Operating Officer

-18,217 0.0157%
29/07/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
-4.97%-2.60%-27.73%+136.18% 3.01B
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.20%+4.29%+26.57%+51.52% 45.81B
-1.35%+2.07%+21.50%+123.25% 43.46B
+0.08%+5.76%+252.19%+925.39% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average -0.24%-0.27%+41.58%+155.73% 38.49B
Weighted average by Cap. +0.34%+0.51%+47.06%+159.44%

Financials

2026 *2027 *
Net sales - -
Net income -542M -484M -447M -405M -757M -51.41B -770M -5.38B -2.13B -26.94B -2.03B -1.99B -84.92B -535M -478M -441M -400M -748M -50.8B -761M -5.31B -2.1B -26.62B -2.01B -1.97B -83.91B
Net Debt -463M -414M -382M -346M -648M -43.99B -659M -4.6B -1.82B -23.05B -1.74B -1.7B -72.66B -511M -456M -421M -382M -714M -48.49B -726M -5.07B -2.01B -25.41B -1.92B -1.88B -80.1B
Projected Income Statement - Annual - Viking Therapeutics, Inc.
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
23/10/26 US$24.53 -5.05% 2,642,047
22/10/26 US$25.83 -2.08% 3,530,546
21/10/26 US$26.38 -1.24% 3,295,042
20/10/26 US$26.71 +6.63% 4,656,930
19/10/26 US$25.05 -0.48% 3,741,079
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Viking Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
25.83USD
Average target price
95.05USD
Spread / Average Target
+267.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Viking Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. VKTX Stock